Olink Holding Past Earnings Performance
Past criteria checks 0/6
Olink Holding has been growing earnings at an average annual rate of 8%, while the Life Sciences industry saw earnings growing at 16% annually. Revenues have been growing at an average rate of 31.7% per year.
Key information
8.0%
Earnings growth rate
85.3%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 31.7% |
| Return on equity | -7.3% |
| Net Margin | -19.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Olink Holding AB (publ) (NASDAQ:OLK) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 28
Is It Time To Consider Buying Olink Holding AB (publ) (NASDAQ:OLK)?
Oct 19We're Interested To See How Olink Holding (NASDAQ:OLK) Uses Its Cash Hoard To Grow
Jul 04A Look At The Intrinsic Value Of Olink Holding AB (publ) (NASDAQ:OLK)
Jun 13At US$21.02, Is It Time To Put Olink Holding AB (publ) (NASDAQ:OLK) On Your Watch List?
May 23Olink Holding (NASDAQ:OLK) Is In A Strong Position To Grow Its Business
Mar 20Calculating The Intrinsic Value Of Olink Holding AB (publ) (NASDAQ:OLK)
Dec 31Olink Holding partners with Discovery Life Sciences to establish commercial platform
Sep 20We're Hopeful That Olink Holding (NASDAQ:OLK) Will Use Its Cash Wisely
Sep 16Olink GAAP EPS of -$0.04, revenue of $27.5M; reaffirms FY22 guidance
Aug 11We're Not Very Worried About Olink Holding's (NASDAQ:OLK) Cash Burn Rate
May 16Olink Holding Plans Strong 2022 Spending Amid Growth Slowdown
May 13Olink Holding AB (publ) (NASDAQ:OLK) Just Reported, And Analysts Assigned A US$29.75 Price Target
Feb 17Companies Like Olink Holding (NASDAQ:OLK) Can Afford To Invest In Growth
Jun 25Revenue & Expenses Breakdown
How Olink Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 171 | -34 | 135 | 38 |
| 31 Dec 23 | 170 | -32 | 130 | 34 |
| 30 Sep 23 | 159 | -19 | 114 | 29 |
| 30 Jun 23 | 147 | -18 | 107 | 27 |
| 31 Mar 23 | 145 | -15 | 103 | 27 |
| 31 Dec 22 | 140 | -13 | 99 | 26 |
| 30 Sep 22 | 126 | -30 | 95 | 28 |
| 30 Jun 22 | 114 | -35 | 92 | 26 |
| 31 Mar 22 | 104 | -36 | 87 | 24 |
| 31 Dec 21 | 95 | -43 | 81 | 22 |
| 30 Sep 21 | 78 | -27 | 70 | 16 |
| 30 Jun 21 | 70 | -26 | 57 | 13 |
| 31 Mar 21 | 60 | -28 | 44 | 11 |
| 31 Dec 20 | 54 | -24 | 33 | 10 |
| 31 Dec 19 | 46 | -37 | 45 | 7 |
Quality Earnings: OLK is currently unprofitable.
Growing Profit Margin: OLK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OLK is unprofitable, but has reduced losses over the past 5 years at a rate of 8% per year.
Accelerating Growth: Unable to compare OLK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OLK is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-8.1%).
Return on Equity
High ROE: OLK has a negative Return on Equity (-7.3%), as it is currently unprofitable.